Medication-Assisted Treatment (MAT) for Addiction

Medication-assisted treatment (MAT) combines FDA-approved medications with counseling and behavioral therapies to treat substance use disorders. For opioid use disorder, three medications have demonstrated strong evidence of effectiveness: buprenorphine (brand name Suboxone), methadone, and naltrexone (brand name Vivitrol). For alcohol use disorder, naltrexone, acamprosate (Campral), and disulfiram (Antabuse) are approved options. According to SAMHSA, MAT has been shown to reduce illicit opioid use, opioid overdose deaths, criminal activity, and infectious disease transmission while improving treatment retention and social functioning. Despite this evidence, MAT remains underutilized due to persistent stigma and misconceptions.

Key Takeaways

• MAT uses FDA-approved medications combined with counseling to treat opioid and alcohol use disorders
• Buprenorphine (Suboxone), methadone, and naltrexone (Vivitrol) are the three FDA-approved medications for opioid use disorder
• Research consistently shows MAT reduces opioid overdose deaths and improves treatment retention
• MAT is not “replacing one addiction with another”; it is evidence-based medical treatment for a chronic condition
• New Jersey has expanded MAT access through removal of the X-waiver requirement and expanded Medicaid coverage
• MAT works best when combined with behavioral therapies and psychosocial support

What Is Medication-Assisted Treatment?

Definition and FDA-Approved Medications

Medication-Assisted Treatment (MAT): An evidence-based approach to addiction treatment that integrates FDA-approved medications with counseling and behavioral therapies to provide a whole-patient approach to substance use disorders.

The term “MAT” is primarily used in reference to opioid and alcohol use disorders, where specific medications have demonstrated effectiveness in clinical trials:

For opioid use disorder:

• Buprenorphine (Suboxone, Subutex, Sublocade, Zubsolv)
• Methadone
• Naltrexone (Vivitrol, ReVia)

For alcohol use disorder:

• Naltrexone (Vivitrol, ReVia)
• Acamprosate (Campral)
• Disulfiram (Antabuse)

These medications are FDA-approved specifically for the treatment of addiction, distinguishing them from off-label use. Each works through a different pharmacological mechanism, and selection depends on the substance, individual medical history, and treatment goals.

How MAT Differs from Abstinence-Only Approaches

Traditional abstinence-based treatment relies exclusively on behavioral interventions, counseling, and peer support without pharmacological assistance. MAT introduces medication as a clinical tool to:

• Stabilize brain chemistry disrupted by chronic substance use
• Reduce cravings that drive relapse
• Block the euphoric effects of substances (naltrexone)
• Prevent withdrawal symptoms that cause treatment dropout (buprenorphine, methadone)
• Provide a medically supervised bridge to sustained recovery

NIDA classifies addiction as a chronic brain disorder and recommends medication as a component of treatment, just as medication is used for other chronic conditions such as diabetes, hypertension, or depression. The distinction is not between medication and recovery, but between different tools available within a comprehensive treatment approach.

MAT Medications Explained

Buprenorphine (Suboxone)

Buprenorphine: A partial opioid agonist that binds to opioid receptors in the brain, providing enough activation to reduce cravings and withdrawal symptoms without producing the full euphoric effect of heroin, fentanyl, or prescription opioids.

Suboxone, the most commonly prescribed formulation, combines buprenorphine with naloxone. The naloxone component is inactive when the medication is taken sublingually (under the tongue) as prescribed, but triggers withdrawal if the medication is injected, serving as a deterrent against misuse.

Key characteristics:

• Administration: Sublingual film or tablet (daily), subcutaneous injection (monthly with Sublocade)
• Setting: Can be prescribed in office-based settings by any provider with a standard DEA license (X-waiver eliminated in 2023)
• Ceiling effect: Partial agonist properties mean there is a dose ceiling for respiratory depression, making buprenorphine safer than full agonists in overdose scenarios
• Flexibility: Patients can fill prescriptions at a pharmacy and take medication at home, allowing for integration with work and daily life
• Induction timing: Must wait until moderate withdrawal begins before starting to avoid precipitated withdrawal

Buprenorphine has become the most widely prescribed MAT medication due to its safety profile, accessibility, and effectiveness. Research published by NIDA demonstrates that buprenorphine treatment reduces opioid use, improves treatment retention, and decreases overdose mortality.

Methadone

Methadone: A full opioid agonist that activates opioid receptors in the brain, eliminating withdrawal symptoms and reducing cravings. Methadone has been used for opioid use disorder treatment since the 1960s and has the longest evidence base of any MAT medication.

Key characteristics:

• Administration: Oral liquid or tablet (daily), dispensed at federally regulated Opioid Treatment Programs (OTPs)
• Setting: OTPs only; patients must visit the clinic daily in early treatment, earning take-home doses over time based on treatment compliance and clinical stability
• Full agonist: Provides complete opioid receptor activation, which may be necessary for patients with high-dose opioid dependence who do not respond adequately to buprenorphine
• Clinical monitoring: Daily dosing at OTPs provides built-in monitoring and clinical contact
• Structured tapering: Can be used for detoxification (tapering doses over weeks) or maintenance (ongoing treatment at a stable dose)

The daily dosing requirement at OTPs is both a strength (ensures medication compliance, provides daily clinical contact) and a limitation (requires daily travel to a clinic, which can conflict with employment and other obligations).

Naltrexone (Vivitrol)

Naltrexone: An opioid antagonist that blocks opioid receptors entirely, preventing opioids from producing euphoria or pain relief. Available as a daily oral tablet (ReVia) or a monthly extended-release intramuscular injection (Vivitrol).

Key characteristics:

• Administration: Monthly injection (Vivitrol) or daily oral tablet (ReVia)
• Setting: Can be prescribed by any licensed provider and administered in any clinical setting
• Mechanism: Blocks opioid effects rather than activating opioid receptors; no abuse potential, no physical dependence on the medication itself
• Requirement: Patient must be fully detoxed from opioids (typically 7-14 days opioid-free) before starting naltrexone, as it will precipitate withdrawal if opioids are still in the system
• Also approved for alcohol use disorder: Reduces alcohol cravings and the pleasurable effects of drinking

Vivitrol’s monthly injection format eliminates daily medication compliance as a variable, which is advantageous for some patients. The primary challenge is completing detox and the opioid-free waiting period required before initiation.

Does MAT Work? What the Evidence Shows

Retention in Treatment

Treatment retention is one of the strongest predictors of long-term recovery outcomes. MAT consistently demonstrates superior retention rates compared to non-medication approaches:

• Buprenorphine and methadone maintenance programs retain patients in treatment at significantly higher rates than detox-only or abstinence-based approaches
• Longer treatment retention with MAT is associated with reduced illicit opioid use, lower rates of infectious disease transmission, and improved social functioning
• Patients who discontinue MAT prematurely experience relapse rates comparable to those who receive no medication treatment

Overdose Prevention

The overdose prevention benefits of MAT are among its most compelling outcomes:

• NIDA research indicates that buprenorphine and methadone significantly reduce opioid overdose mortality
• MAT reduces the risk of fatal overdose during the highest-risk period: early recovery, when tolerance has decreased but relapse risk remains elevated
• Naltrexone’s complete opioid receptor blockade provides protection against overdose from opioid use while the medication is active

Long-Term Outcomes

Research on MAT outcomes supports its use as a long-term treatment strategy:

• Studies demonstrate that patients who remain on MAT for at least one year show better outcomes than those who discontinue earlier
• There is no established optimal duration for MAT; clinical guidelines recommend that treatment duration be individualized based on clinical assessment, not arbitrary timelines
• Gradual, medically supervised tapering may be appropriate for some patients, while others benefit from indefinite maintenance

Common Misconceptions About MAT

Several persistent misconceptions contribute to underutilization of MAT:

“MAT is just replacing one drug with another.” This is the most common and most harmful misconception. MAT medications stabilize brain chemistry, allowing patients to function normally without euphoria, sedation, or impairment. This is analogous to using insulin for diabetes or antihypertensives for high blood pressure. The medication treats a physiological condition; it does not replicate the addiction.

“You’re not really sober if you’re on MAT.” Recovery is defined by improved functioning, health, and quality of life, not solely by the absence of all medications. SAMHSA, ASAM, and NIDA all define MAT patients as being in recovery. Some 12-step communities have historically stigmatized MAT, though many are evolving on this point.

“MAT should only be short-term.” There is no evidence supporting arbitrary time limits on MAT. Premature discontinuation is associated with significantly elevated relapse and overdose risk. The decision to taper should be made collaboratively between patient and provider based on clinical indicators, not external pressure.

“MAT is a crutch.” Medications that improve treatment outcomes, reduce mortality, and support functional recovery are medical tools, not crutches. This framing is not applied to medications for other chronic conditions and should not be applied to addiction treatment.

Accessing MAT in New Jersey

New Jersey has significantly expanded MAT access in recent years:

• X-waiver elimination: Since 2023, any provider with a standard DEA license can prescribe buprenorphine. The previous requirement for a special DEA waiver created an unnecessary barrier to access.
• OTP availability: NJ has Opioid Treatment Programs (methadone clinics) located across the state, with coverage through NJ FamilyCare (Medicaid) and most private insurers.
• NJ FamilyCare (Medicaid): Covers all FDA-approved MAT medications, including Suboxone, methadone, and Vivitrol, as well as associated counseling and monitoring services.
• Telehealth prescribing: NJ allows buprenorphine prescribing via telehealth, further expanding access for patients in rural areas or with transportation barriers.
• Hub-and-spoke model: NJ has implemented a regional MAT access system connecting primary care providers with specialized addiction medicine support.

Patients seeking MAT in New Jersey can contact 1-844-ReachNJ for referrals to buprenorphine prescribers and OTPs. For more on opioid detox protocols that may precede MAT initiation, and for information about medical detox more broadly, see our related guides.

---

This is part of our complete guide to Types of Addiction Treatment.